William M. Southerland to Fluorouracil
This is a "connection" page, showing publications William M. Southerland has written about Fluorouracil.
Connection Strength
0.108
-
Das JR, Fryar-Tita EB, Zhou Y, Green S, Southerland WM, Bowen D. Sequence-dependent administration of 5-fluorouracil maintains methotrexate antineoplastic activity in human estrogen-negative breast cancer and protects against methotrexate cytotoxicity in human bone marrow. Anticancer Res. 2007 Nov-Dec; 27(6B):3791-9.
Score: 0.019
-
Fryar-Tita EB, Das JR, Davis JH, Desoto JA, Green S, Southerland WM, Bowen D. Raloxifene and selective cell cycle specific agents: a case for the inclusion of raloxifene in current breast cancer treatment therapies. Anticancer Res. 2007 May-Jun; 27(3B):1393-9.
Score: 0.018
-
Das JR, Fryar-Tita EB, Green S, Southerland WM, Bowen D. Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow. Anticancer Res. 2007 Mar-Apr; 27(2):825-33.
Score: 0.018
-
Das JR, Fryar EB, Green S, Southerland WM, Bowen D. The protection against trimetrexate cytotoxicity in human bone marrow by sequence-dependent administration of raloxifene, 5-fluorouracil/trimetrexate. Anticancer Res. 2006 Nov-Dec; 26(6B):4279-86.
Score: 0.018
-
Fryar EB, Das JR, Davis JH, Desoto JA, Laniyan I, Southerland WM, Bowen D. Raloxifene attenuation of 5-FU/methotrexate cytotoxicity in human breast cancer cells: the importance of sequence in combination chemotherapy. Anticancer Res. 2006 May-Jun; 26(3A):1861-7.
Score: 0.017
-
Das JR, Fryar EB, Epie NN, Southerland WM, Bowen D. Raloxifene attenuation of methotrexate cytotoxicity in human bone marrow by sequence-dependent administration of raloxifene, 5-FU/methotrexate. Anticancer Res. 2006 May-Jun; 26(3A):1877-83.
Score: 0.017